Therapies for type 1 diabetes: current scenario and future perspectives
V Pathak, NM Pathak, CL O'Neill… - Clinical Medicine …, 2019 - journals.sagepub.com
Type 1 diabetes (T1D) is caused by autoimmune destruction of insulin-producing β cells
located in the endocrine pancreas in areas known as islets of Langerhans. The current …
located in the endocrine pancreas in areas known as islets of Langerhans. The current …
SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with …
Y Ye, M Bajaj, HC Yang, JR Perez-Polo… - … drugs and therapy, 2017 - Springer
Purpose We assessed whether (1) dapagliflozin (Dapa, an SGLT2-inhibitor) attenuates the
deterioration of heart function Nlrp3 and inflammasome activation in diabetic mice.(2) The …
deterioration of heart function Nlrp3 and inflammasome activation in diabetic mice.(2) The …
[HTML][HTML] Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Objective Structurally-improved GIP analogs were developed to determine precisely
whether GIP receptor (GIPR) agonism or antagonism lowers body weight in obese mice …
whether GIP receptor (GIPR) agonism or antagonism lowers body weight in obese mice …
New insights into beta-cell GLP-1 receptor and cAMP signaling
A Tomas, B Jones, C Leech - Journal of molecular biology, 2020 - Elsevier
Harnessing the translational potential of the GLP-1/GLP-1R system in pancreatic beta cells
has led to the development of established GLP-1R-based therapies for the long-term …
has led to the development of established GLP-1R-based therapies for the long-term …
Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice
P Millar, N Pathak, V Parthsarathy… - Journal of …, 2017 - joe.bioscientifica.com
This study assessed the metabolic and neuroprotective actions of the sodium glucose
cotransporter-2 inhibitor dapagliflozin in combination with the GLP-1 agonist liraglutide in …
cotransporter-2 inhibitor dapagliflozin in combination with the GLP-1 agonist liraglutide in …
Dapagliflozin ameliorates the formation and progression of experimental abdominal aortic aneurysms by reducing aortic inflammation in mice
H Liu, P Wei, W Fu, C Xia, Y Li, K Tian… - Oxidative medicine …, 2022 - Wiley Online Library
Background. Dapagliflozin, a sodium glucose transporter protein‐2 (SGLT‐2) inhibitor,
reduces the risk for cardiovascular diseases. However, the influence of dapagliflozin on …
reduces the risk for cardiovascular diseases. However, the influence of dapagliflozin on …
Dapagliflozin added to metformin reduces perirenal fat layer in type 2 diabetic patients with obesity
G Cuatrecasas, F De Cabo, MJ Coves, I Patrascioiu… - Scientific Reports, 2024 - nature.com
Sodium-glucose co-transporters type 2 inhibitors (SLGT2i) are highly effective in controlling
type 2 diabetes, but reported beneficial cardiovascular effects suggest broader actions on …
type 2 diabetes, but reported beneficial cardiovascular effects suggest broader actions on …
Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential
Glucose-dependent insulinotropic hormone (GIP) and glucagon-like peptide-1 (GLP-1) are
incretin hormones that exert an array of beneficial actions on metabolism and cognitive …
incretin hormones that exert an array of beneficial actions on metabolism and cognitive …
Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic GluCreERT2; ROSA26-eYFP mice
D Sarnobat, RC Moffett, VA Gault, N Tanday… - Peptides, 2020 - Elsevier
Enzyme-resistant long-acting forms of the gut-derived peptide hormones, glucose-
dependent insulinotropic polypeptide (GIP), xenin and oxyntomodulin (Oxm) have been …
dependent insulinotropic polypeptide (GIP), xenin and oxyntomodulin (Oxm) have been …